{"filing":{"accession_number":"0001104659-26-099200","cik":"0000786947","ticker":null,"company_name":"ACURA PHARMACEUTICALS, INC","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-14","primary_document":"tm2623715d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926099200/tm2623715d1_8k.htm"},"events":[{"id":28822,"run_id":26378,"accession_number":"0001104659-26-099200","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Acura Pharmaceuticals entered into an amended secured promissory note with Abuse Deterrent Pharma, LLC, documenting cumulative principal of approximately $11.1 million as of August 14, 2026, including a $200,000 loan drawdown. The company faces material liquidity pressure and has stated that absent additional financing by late September 2026, it will be required to scale back operations or seek bankruptcy protection.","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30877,"accession_number":"0001104659-26-099200","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a material definitive agreement involving a $200,000 loan from Abuse Deterrent Pharma, LLC on August 14, 2026, which brings the total principal balance under the consolidated note to $11,094,279. While the immediate loan is modest, the cumulative debt burden and the company's explicit statement that \"in the absence of the receipt of additional financing by late-September 2026, we will be required to scale back our operations...or seek protection under applicable bankruptcy laws\" indicates material financial stress and going-concern risk. The debt issuance itself is the primary disclosed event, though the existential liquidity crisis is also evident.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:26:48.793638+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30879,"accession_number":"0001104659-26-099200","item_number":"2.01","item_title":"Completion of Acquisition","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses an amended loan schedule to a secured promissory note between Acura Pharmaceuticals and Abuse Deterrent Pharma, LLC, documenting cumulative principal of approximately $11.1 million as of August 2026. While labeled Item 2.01 (Completion of Acquisition or Disposition), the actual substance is the creation and amendment of a direct financial obligation—a secured promissory note with ongoing loan tranches. This is most consistent with debt_issuance rather than M\u0026A activity, as no acquisition or disposition of assets is described; instead, the filing documents the terms and schedule of debt financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:26:48.793638+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30880,"accession_number":"0001104659-26-099200","item_number":"2.03","item_title":"Creation of a Direct Financial","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an amended loan schedule to a secured promissory note with Abuse Deterrent Pharma, LLC, documenting cumulative principal of $11,094,279 as of August 14, 2026. The forward-looking statements explicitly reference the company's dependence on funding from this lender and the critical December 31, 2026 deadline for both FDA acceptance of an NDA for LTX-03 and repayment of the secured promissory note, indicating this debt is material to the company's operations and survival.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:26:48.793638+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30877,"accession_number":"0001104659-26-099200","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a material definitive agreement involving a $200,000 loan from Abuse Deterrent Pharma, LLC on August 14, 2026, which brings the total principal balance under the consolidated note to $11,094,279. While the immediate loan is modest, the cumulative debt burden and the company's explicit statement that \"in the absence of the receipt of additional financing by late-September 2026, we will be required to scale back our operations...or seek protection under applicable bankruptcy laws\" indicates material financial stress and going-concern risk. The debt issuance itself is the primary disclosed event, though the existential liquidity crisis is also evident.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:26:48.793638+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-08-20"},{"id":30879,"accession_number":"0001104659-26-099200","item_number":"2.01","item_title":"Completion of Acquisition","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses an amended loan schedule to a secured promissory note between Acura Pharmaceuticals and Abuse Deterrent Pharma, LLC, documenting cumulative principal of approximately $11.1 million as of August 2026. While labeled Item 2.01 (Completion of Acquisition or Disposition), the actual substance is the creation and amendment of a direct financial obligation—a secured promissory note with ongoing loan tranches. This is most consistent with debt_issuance rather than M\u0026A activity, as no acquisition or disposition of assets is described; instead, the filing documents the terms and schedule of debt financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:26:48.793638+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-08-20"},{"id":30880,"accession_number":"0001104659-26-099200","item_number":"2.03","item_title":"Creation of a Direct Financial","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an amended loan schedule to a secured promissory note with Abuse Deterrent Pharma, LLC, documenting cumulative principal of $11,094,279 as of August 14, 2026. The forward-looking statements explicitly reference the company's dependence on funding from this lender and the critical December 31, 2026 deadline for both FDA acceptance of an NDA for LTX-03 and repayment of the secured promissory note, indicating this debt is material to the company's operations and survival.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:26:48.793638+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-08-20"}]}